Supplementary Appendix to:

South African Population Immunity and Severe Covid-19 with Omicron Variant

Shabir A. Madhi, Ph.D.,^{1,2} Gaurav Kwatra, Ph.D.,^{1,2} Jonathan E. Myers, M.D.,³ Waasila Jassat, M.Med.,⁴ Nisha Dhar, Ph.D.,¹ Christian K. Mukendi, M.Sc.,¹ Amit J. Nana, B.Sc.,¹ Lucille Blumberg, M.Med.,^{4,5} Richard Welch, B.Sc.,⁴ Nicoletta Ngorima-Mabhena, M.B.Ch.B.,⁶ Portia C. Mutevedzi, Ph.D.¹

¹South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa ²African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa ³Centre for Environmental and Occupational Health Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa ⁴National Institute for Communicable Diseases, Johannesburg, South Africa ⁵Right To Care, Gauteng, South Africa ⁶ResearchLinkMe, Johannesburg, South Africa

Supplementary Appendix

Contents	Page
Supplementary Methods	3
Study design and sample size	3
Data collection	3
Sample collection and processing	3
Serology analysis	4
Covid-19 data sources	5
Statistical analyses	6
Supplementary Figures	8
Figure S1: Cumulative number and percentage of dried blood spots collected from	8
November 22, 2021 to December 9, 2021	
Figure S2: Seroprevalence across sub-districts in Gauteng Province.	9
Figure S3: Incidence of Covid-19 cases, hospital admissions, and in-hospital deaths over the	10
time period of the pandemic in Gauteng Province, South Africa, stratified by sex	
Figure S4: Covid-19 daily case rates, weekly hospital admission rates, weekly excess death	11
rates, and daily reported death rates over the time period of the pandemic in the five	
districts of Gauteng Province, South Africa, as of January 12, 2022	
Supplementary Tables	14
Table S1: Demographics of sampling area in serosurvey	14
Table S2. Representativeness of the seroepidemiological survey population to the general	15
population of Gauteng Province and of South Africa	
Table S3: Vaccination rates in Gauteng Province, South Africa, by district, age group, and	16
vaccine received, as of November 25, 2021	
Table S4: Seroprevalence of SARS-CoV-2 anti-spike (anti-S) or anti-nucleocapsid (anti-N)	17
immunoglobulin G (IgG) Gauteng Province across the Districts and sub-Districts	
Table S5. Number and incidence per 100,000 population of Covid-19 cases, in Gauteng	19
Province by Covid-19 wave, stratified by age and by gender	
Table S6. Number and incidence per 100,000 population of hospitalizations in Gauteng	20
Province by Covid-19 wave, stratified by age and by gender	
Table S7. Number and incidence per 100,000 population of recorded deaths in Gauteng	21
Province by Covid-19 wave, stratified by age and by gender	
Supplementary References	22

Supplementary Methods

Study design and sample size

This survey included households that had been sampled during the first seroprevalence survey, which was conducted done from November 4, 2020, to January 22, 2021,¹ and included an additional 10% households per cluster to accommodate for non-participation. The sample size calculation was based on the Africa Centres for Disease Control and Prevention generic protocol for a population-based, age- and gender-stratified seroprevalence survey study for SARS-CoV-2² and on the World Health Organization population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection.³ Assuming a seroprevalence of 10%, response rate of 0.75, intra-cluster correlation (ICC) of 0.33, with a precision of 0.1, α of 0.05, and design effect of 3.31, the resultant required overall survey sample size was 6025 (61 to 1948 by sub-district) individuals. Design effect of 3.31 was based on the observation that seroprevalence rates vary by geographic area within the same region.² A conservative ICC of 0.33 was used considering clustering nature of respiratory diseases.

Three-stage sampling was employed; first, the GeoTeraImage (GTI)-2019 dataset

(https://geoterraimage.com/), which comprises more than 16,000 "small areas" used for demarcating census areas was stratified by housing type. Systematic random cluster selection without replacement and probability proportional to estimated size (PPES) was then used to select clusters. Finally, a random sample of 9 households was selected from each cluster. The number of clusters, and hence the number of households selected per sub-district, was proportional to the sub-district population size. The average household size was assumed to be 4 individuals based on census data with a target of 9 households per cluster. All individuals residing in sampled households, irrespective of age, were eligible.

Data collection

Electronic data collection was done using android tablets with real time synchronisation of data into a central KoBo Collect database. The questionnaire comprised a household module with household membership listing and socio-demographic characteristics. The individual module included individual-level questions on socio-demographics, previous Covid-19 diagnosis, Covid-19 vaccination, comorbidities, and health seeking behaviour (see Supplementary Appendix 2).

Sample collection and processing

Dried blood spots (DBS) were obtained by finger-prick with a single-use lancet needle, with 3–5 DBS collected on filter cards (Ahistrom Munksjo, Germany, catalogue number 8.460.0013.A). The DBS were dried for 3 hours at room temperature, packed into plastic pouches with silica-gel sachets, transported

3

to the laboratory, and stored at -20° C until analysis.¹ Elution of antibodies from DBS card specimens was performed as previously described.⁴ Briefly, one spot was cut from the filter card using a 6 mm hole punch and added to 600 µl of assay buffer. The spot was kept in a shaker at 2–8°C overnight for elution and the following day was centrifuged at 2000 g for 10 min before analysis.

Serology analysis

SARS-CoV-2 full-length spike and nucleocapsid (N) protein immunoglobulin G (IgG) were measured by quantitative assay on the Luminex platform. The expression plasmid encoding for the SARS-CoV-2 full-length spike were obtained from Florian Krammer, Mount Sinai, USA. The recombinant spike protein was expressed as described previously,⁵ and N protein was obtained from BioTech, Africa (Cat no# BA25-P, South Africa). Proteins were coupled to magnetic microsphere beads (Bio-Rad, USA) using a two-step carbodiimide reaction.⁶ Samples were analyzed in single-plex, and each plate included two inhouse control sera. Bead fluorescence was read with the Bio-Plex 200 instrument (Bio-Rad) using Bio-Plex manager 5.0 software (Bio-Rad).

An in-house reference serum was developed by pooling convalescent serum from adult SARS-CoV-2positive patients. This interim reference serum was calibrated against research reagent NIBSC 20/130 and the first WHO International Standard for anti-SARS-CoV-2 NIBSC 20/136. Binding antibody unit (BAU) values assigned to the in-house reference serum were 2819 BAU/mL for spike IgG and 1101 BAU/mL for N protein IgG. The assay was further evaluated for detection of antibodies against SARS-CoV-2 using Covid-19 convalescent plasma panel NIBSC 20/118.

The IgG assay using DBS cards was validated using paired plasma and DBS cards (collected from hospitalized participants who were SARS-CoV-2-positive by PCR test) for detection of SARS-CoV-2 IgG antibodies. There was a good correlation between IgG values measured by the two sampling methods: r = 0.935 and r = 0.965 for receptor binding domain and full-length spike protein of SARS-CoV-2, respectively. Bland-Altman assessment showed good agreement between two sampling methods.⁴

Serum samples collected prior to 2020 (n = 31) and serum samples obtained from randomly selected (n = 15) participants who were SARS-CoV-2-positive on PCR test and who had serial blood sampling before and after symptom onset (including individuals with mild-to-moderate illness and asymptomatic infections) were used for the analysis of assay specificity and sensitivity, and for calculation of the threshold for IgG seropositivity. Based on IgG titers from pre-Covid-19 era samples, baseline and post-infection samples of participants who were SARS-CoV-2-positive on PCR test, 32 BAU/mL and 15

4

BAU/mL were selected as the thresholds indicative of seropositivity for full-length spike and N protein IgG, respectively. The sensitivity of the assay to detect seropositivity at the selected thresholds was 100% (15/15) and 85% (12/14) for samples taken >14 days following the SARS-CoV-2-positive PCR test for full-length spike and N protein IgG, respectively.

Covid-19 data sources

Daily case, hospital admission, and reported death data were sourced from the DATCOV database, which is hosted by South Africa's National Institute for Communicable Diseases,^{7,8} as described previously.⁹ The system was developed during the course of the first wave of Covid-19, with gradual onboarding of facilities. Hence, data from DATCOV could underestimate hospitalized cases in the first wave relative to subsequent waves. The hospitalized cases include individuals with Covid-19 as well as coincidental infections identified as part of routine testing for SARS-CoV-2 of individuals admitted to the facilities to assist in triaging of patients in the hospital.

DATCOV was initially implemented in eight sentinel public hospital sites but within six months was adopted as South Africa's national Covid-19 hospital surveillance system. In addition, the South African National Department of Health placed data capturers at all public hospitals in 8 provinces (excluding Western Cape, which has an electronic information system that feeds into DATCOV). This has ensured the quality and completeness of data submission of DATCOV. By January 7, 2021, 481,209 admissions and 97,931 deaths had been reported to DATCOV from 259 private and 407 public hospitals in South Africa. It is believed that the reporting of Covid-19 admissions to DATCOV is near-complete and representative of Covid-19 admissions across the country.

DATCOV contains data on all individuals, irrespective of age, who had a positive reverse transcription polymerase chain reaction (RT-PCR) assay or antigen test for SARS-CoV-2, with a confirmed duration of stay in hospital of one full day or longer, regardless of reason for admission. The DATCOV case report form (CRF) was adapted from the World Health Organization (WHO) COVID-19 case reporting tool,¹⁰ recording the following variables: demographic data (age, sex, race), exposures such as occupation, and potential risk factors such as comorbid disease(s) and pregnancy status. Additional variables included level of treatment, complications, treatment, and outcomes of the hospital admission (discharged, transferred out to another hospital, or died).

5

Data on excess weekly mortality were sourced from the weekly report by the Burden of Disease Research Unit of the South African Medical Research Council.¹¹ Within the glossary to each report, the following statements are provided regarding the definition and calculation of excess mortality rates:

- "Excess deaths: There is no universal definition of, or understanding of what is meant by,
 "excess mortality". It is a term used in epidemiology and public health that refers to the number of deaths that are occurring above what we would normally expect. The WHO uses the term to describe "Mortality above what would be expected based on the non-crisis mortality rate in the population of interest. Excess mortality is thus mortality that is attributable to the crisis conditions. It can be expressed as a rate (the difference between observed and non-crisis mortality rates), or as a total number of excess deaths."
- "Excess natural deaths associated with COVID-19: Generally, the number of excess deaths per week is calculated as the number of all-cause deaths in that week less the number that might be assumed to have occurred had there not been the epidemic (i.e. the counterfactual number), provided that the counterfactual is lower. However, this approach has generally only been applied to countries where deaths have been tracking the counterfactual before the onset of significant numbers of COVID-19 related deaths. The method provides a poor estimate of the numbers of COVID-19 and collateral deaths in the early stages of the epidemic when this is not the case. Thus, we estimated the numbers of COVID-19 and collateral deaths less a baseline number determined as a proportion of the predicted number. By the end of the 1st wave of the pandemic, the predicted values have been used as the counterfactual."

Statistical analyses

We estimated anti-SARS-CoV-2 seroprevalence as the proportion of individuals testing positive for either spike or N protein IgG and assessed variability by age, gender, vaccination status, and sub-district of residence. Factors associated with seropositivity were determined using generalized linear models with log link to estimate risk ratios. These were unadjusted, univariable analyses for each risk factor. Confidence intervals have not been adjusted for multiplicity and should not be used for inference. Comorbidities included any of self-reported hypertension, diabetes, asthma, HIV positive status, cancer, tuberculosis, stroke, or lung, liver, kidney, or heart disease. Stata (version 16.1) was used for data analyses, with sampling weights calculated based on the sampling frame. Data analyses techniques used clustering adjusted for at the household level. For epidemiological analyses, daily rates were smoothed using locally weighted scatterplot smoothing (Lowess) in STATA version 16.1 using a bandwidth of 0.06, which closely matches the 7-day moving average but which provides a smoother graph line, allowing the minimum values at the beginning and end of each Covid-19 wave to be easily identified. These minima are taken as cut-points for each wave, with no overlap and no data omitted from analysis. Raw counts were obtained at these cut-points for cumulative numbers for each wave. Weekly excess death rates were unsmoothed. Data on excess mortality were unavailable by age group and sex.

Figure S1: Cumulative number and percentage of dried blood spots collected from November 22, 2021 to December 9, 2021.

By November 25, when the Omicron variant was first reported, 83% of dried blood spot (DBS) samples had been collected.




Figure S2: Seroprevalence across sub-districts in Gauteng Province.

Sampling period from October 22, 2021 through to December 9, 2021.





Figure S3: Incidence of Covid-19 cases, hospital admissions, and in-hospital deaths over the time period of the pandemic in Gauteng Province, South Africa, stratified by sex

Panels show data for (A) males and (B) females. A







Figure S4: Covid-19 daily case rates, weekly hospital admission rates, weekly excess death rates, and daily reported death rates over the time period of the pandemic in the five districts of Gauteng Province, South Africa, as of January 12, 2022


All data are from the National Institute for Communicable Diseases daily databases except for weekly excess deaths. Excess mortality from natural causes was defined per and sourced from the South African Medical Research Council; the excess mortality data are reported through to January 8, 2021.¹¹ Stratified excess mortality data were unavailable for Sedibeng and West Rand.¹¹ The solid vertical black line represents the start of the fourth, Omicron-dominant wave on November 15, 2022. Changes in testing rates, particularly the lower rates during Wave 1 due to constraints in laboratory capacity and prioritization of testing for hospitalized individuals, prevent direct comparisons, especially in terms of case numbers during the first wave in relation to the subsequent waves. Cases include asymptomatic and symptomatic individuals. Cumulative reported cases were sourced from the National Department of Health.¹² Hospitalization data are from DATCOV, hosted by the National Institute for Communicable Disease,⁷ as described previously.⁹ The system was developed during the course of the first wave, with gradual onboarding of facilities; hence, these data could underestimate hospitalized cases in the first wave relative to subsequent waves. The hospitalized cases include individuals with Covid-19, as well as coincidental infections identified as part of routine testing for SARS-CoV-2 of individuals admitted to the facilities to assist in triaging of patients in the hospital. Cumulative reported deaths were sourced from the National Department of Health.¹² As absolute rates differ between districts, different Y-axis scales have been used for each individual district in order to provide clarity and aid visual interpretation of the trends in each district.

Johannesburg District




(tick marks show 1st of month)

Ekurhuleni District




(tick marks show 1st of month)






City of Tshwane District



(tick marks show 1st of month)



(tick marks show 1st of month)

District / Sub-district	Population – no.*	Participants in survey	Survey time-period, 2021	Population density – persons/km ^{2†}	Living in informal housing settlement – %†
Gauteng Province	15,176,113	7010	Oct 22–Dec 09	737	20.1%
Johannesburg District	5,606,238	2468	Oct 22–Dec09	3400	18.6%
Johannesburg A	779,519	333	Oct 25–Nov 23		
Johannesburg B	435,241	197	Nov 16–25		
Johannesburg C	799,980	444	Oct 25–Dec 08		
Johannesburg D	1,396,243	646	Oct 22–Dec 09		
Johannesburg E	601,433	161	Nov 23–Dec 08		
Johannesburg F	751,484	243	Oct 27–Dec 03		
Johannesburg G	842,339	444	Oct25–Dec03		
Ekurhuleni District	3,825,650	1861	Oct 22–Dec 08	1609	22.6%
Ekurhuleni E1	626,517	353	Oct 25–Dec 06		
Ekurhuleni E2	455,262	252	Oct 22–Dec 08		
Ekurhuleni N1	708,290	358	Nov 05–30		
Ekurhuleni N2	697,175	258	Nov 16–Dec 05		
Ekurhuleni S1	673,758	210	Nov 07–Dec 02		
Ekurhuleni S2	664,648	430	Oct 25–Dec 08		
Sedibeng District	1,084,503	564	Oct 25–Dec 03	220	16.3%
Emfuleni	127,419	408	Oct 25–Dec 03		
Lesedi	126,285	104	Nov 16–23		
Midvaal	830,798	52	Nov 09–26		
City of Tshwane District	3,709,635	1464	Oct 25–Dec 09	464	19.3%
Tshwane 1	1,032,885	471	Oct 28–Dec 09		
Tshwane 2	436,950	175	Nov 04–25		
Tshwane 3	730,788	229	Nov 03–Dec 05		
Tshwane 4	482,448	78	Oct 26–Dec 01		
Tshwane 5	119,190	204	Oct 25–Dec 06		
Tshwane 6	768,446	245	Nov 12–Dec 07		
Tshwane 7	138,928	62	Nov 29–Dec 08		
West Rand District	950,088	653	Oct 25–Dec 09	200	23.9%
Mogale City	435,254	149	Oct 25–Dec 09		
Rand West City	300,960	261	Nov 03–Dec 09		
Merafong City	213,874	243	Nov 02–Dec 09		

Table S1: Demographics of sampling area in serosurvey.

*Population estimates obtained from the STATS-SA provincial mid-year population estimates.

⁺Only available at the district level.

Disease	Coronavirus disease 2019 (Covid-19)
Special considerations related to:	
Sex and gender	Covid-19 case rates are slightly higher in females compared to males
Age	Covid-19 incidence (cases per 100,000 persons) increases with age; the lowest incidence is in those aged <5years (862.4), and incidence increases linearly with increase in age, with the highest incidence in those aged 50–54 years (11,160.6). Covid-19 incidence in those aged
	>60 years is lower than in those aged 20–59 years
Race or ethnic group	There is no evidence that Covid-19 disproportionately affects people of a specific race or ethnicity. In South Africa, 81% of the population is Black African.
Geography	Covid-19 incidence varies by geographic area. ^{1,13,14} Gauteng Province has the highest incidence rate in South Africa, accounting for 33% of the total cases in the country. Across the world, Covid-19 incidence and severity vary widely associated with underlying population structures; countries with older populations have more Covid-19 cases.
Socio-economic status	In two seroprevalence surveys conducted in Gauteng Province, inclusive of this one, there was lower seroprevalence in informal settlements compared to formal stand-alone houses and higher seroprevalence in blocks of flats/high-rise buildings. ¹ In Gauteng Province, 20.1% of the population resides in informal settlements, ¹⁵ ranging from 16.3% to 23.9% across the five districts. Similarly, of our survey sample, 16.4% reside in informal settlements.
Overall representativeness of this survey	In South Africa and Gauteng Province, females constitute 51.2% and 49.9% of the population, respectively. Biological gender at birth was reported by the participants and captured as male, female, or declined to respond. This survey comprised 58% females, and thus slightly overrepresented females. Covid-19 incidence is higher in older populations and Africa generally has younger populations compared to Europe and America. 73.6% of this survey population were aged 15–59 years comparable to 67.7% in Gauteng Province and South Africa. Our survey sample was representative of the underlying population residential types, an indicator for socio-economic status. Seroprevalence estimates by age and gender from this survey are consistent with Covid-19 epidemiological data in South Africa. ¹³

Table S2. Representativeness of the seroepidemiological survey population to the general population of Gauteng Province and of South Africa¹³

Place	Total target population – no.	At least one vaccine dose – no. (%)	Two doses of either vaccine – no. (%)	One dose of BNT162b2* – no. (%)	Two doses of BNT162b2* – no. (%)	One dose of Ad26.COV2.S† – no. (%)	Sisonke2 study Ad26.COV2.S booster – no. (%)
Gauteng Province							
Overall	12,191,569	4,386,646 (36.0)	2,452,017 (20.1)	3,261,822 (26.8)	2,417,414 (19.8)	1,124,824 (9.2)	34,603 (0.3)
12–18 yr	1,447,321	158,646 (11.0)	35,993 (2.5)	139,691 (9.7)	35,933 (2.5)	18,955 (1.3)	60 (<0.1)
>18 to 50 yr	8,328,203	2,748,011 (33.0)	1,329,064 (16.0)	1,880,401 (22.6)	1,306,882 (15.7)	867,610 (10.4)	22,182 (0.3)
>50 yr	2,416,045	1,479,288 (61.2)	1,086,664 (45.0)	1,241,139 (51.4)	1,074,303 (44.5)	238,149 (9.9)	12,361 (0.5)
Not defined	n/a	701	296	591	296	110	0
Johannesburg							
Overall	4,643,131	1,879,851 (40.5)	1,097,108 (23.6)	1,470,587 (31.7)	1,074,606 (23.1)	409,264 (8.8)	22,502 (0.5)
12–18 yr	525,964	71,743 (13.6)	17,180 (3.3)	65,326 (12.4)	17,137 (3.3)	6417 (1.2)	43 (<0.1)
>18 to 50 yr	3,251,303	1,220,750 (37.5)	651,704 (20.0)	905,004 (27.8)	637,022 (19.6)	315,746 (9.7)	14,682 (0.5)
>50 yr	865,864	586,946 (67.8)	428,063 (49.4)	499,909 (57.7)	420,286 (48.5)	87,037 (10.1)	7,777 (0.9)
Not defined	n/a	412	161	348	161	64	0
Ekurhuleni							
Overall	3,090,769	960,276 (31.1)	555,245 (18.0)	749,337 (24.2)	551,445 (17.8)	210,939 (6.8)	3800 (0.1)
12–18 yr	368,349	35,077 (9.5)	8264 (2.2)	32,255 (8.8)	8261 (2.2)	2822 (0.8)	3 (<0.1)
>18 to 50 yr	2,115,789	595,824 (28.2)	289,862 (13.7)	423,366 (20.0)	287,462 (13.6)	172,458 (8.2)	2400 (0.1)
>50 yr	606,631	329,270 (54.3)	257,075 (42.4)	293,619 (48.4)	255,678 (42.1)	35,651 (5.9)	1397 (0.2)
Not defined	n/a	105	44	97	44	8	0
Sedibeng							
Overall	771,158	218,705 (28.4)	109,121 (14.2)	144,983 (18.8)	108,287 (14.0)	73,722 (9.6)	834 (0.1)
12–18 yr	101,461	7838 (7.7)	1362 (1.3)	6101 (6.0)	1362 (1.3)	1737 (1.7)	0
>18 to 50 yr	475,958	119,966 (25.2)	46,646 (9.8)	66,441 (14.0)	46,165 (9.7)	53,525 (11.2)	481 (0.1)
>50 yr	193,738	90,881 (46.9)	61,104 (31.5)	72,424 (37.4)	60,751 (31.4)	18,457 (9.5)	353 (0.2)
Not defined	n/a	20	9	17	9	3	0
City of Tshwane							
Overall	2,933,611	1,029,116 (35.1)	531,597 (18.1)	675,860 (23.0)	524,529 (17.9)	353,256 (12.0)	7068 (0.2)
12–18 yr	356,800	31,733 (8.9)	7533 (2.1)	26,069 (7.3)	7519 (2.1)	5664 (1.6)	14 (<0.1)
>18 to 50 yr	1,996,039	621,768 (31.2)	254,539 (12.8)	356,047 (17.8)	250,172 (12.5)	265,721 (13.1)	4367 (0.2)
>50 yr	580,771	375,470 (64.7)	269,450 (46.4)	293,632 (50.6)	266,763 (45.9)	81,838 (14.1)	2687 (0.5)
Not defined	n/a	145	75	112	75	33	0
West Rand							
Overall	752,898	298,698 (39.7)	158,946 (21.1)	221,055 (29.4)	158,547 (21.1)	77,643 (10.3)	399 (0.1)
12–18 yr	94,744	12,255 (12.9)	1654 (1.7)	9940 (10.5)	1654 (1.7)	2315 (2.4)	0
>18 to 50 yr	489,114	189,703 (38.8)	86,313 (17.6)	129,543 (26.5)	86,061 (17.6)	60,160 (12.3)	252 (0.1)
>50 yr	169,039	96,721 (57.2)	70,972 (42.0)	81,555 (48.2)	70,825 (41.9)	15,166 (9.0)	147 (0.1)
Not defined	n/a	19	7	17	7	2	0

Table S3: Vaccination rates in Gauteng Province, South Africa, by district, age group, and vaccine received, as of November 25, 2021.

*The current recommended dosing schedule for BNT162b2 in South Africa is 2 doses for individuals aged >18 years and 1 dose for children aged 12–18 years. †The current recommended dosing schedule of Ad26.COV2.S in South Africa is 1 dose for all age groups. A booster dose is available to healthcare workers through the Sisonke2 study. n/a, not applicable

Table S4: Seroprevalence of SARS-CoV-2 anti-spike (anti-S) or anti-nucleocapsid (anti-N) immunoglobulin G (IgG) Gauteng Province across the Districts and sub-Districts irrespective of Covid-19 vaccination status.

District / sub- district	Population – no.*	Participants in survey	Anti-S or anti-N – no. (%) [95% CI]	Anti-S IgG reactive only – no.(%) [95% CI]	Overall anti-N IgG reactive – no. (%) [95% CI]	Overall anti-S IgG reactive – no. (%) [95%] CI)
Gauteng Province	15,176,113	7010	5125 (73.1)	2275 (32.5)	2850 (40.7)	4906 (70.0)
			[72.0–74.1]	[31.4–33.5]	[39.5–41.8]	[68.9–71.0]
Johannesburg	5,606,238	2468	1881 (76.2)	794 (32.2)	1087 (44.0)	1792 (72.6)
District			[74.5–77.8]	[30.3–34.0]	[42.1–46.0]	[70.8–74.3]
Johannesburg A	779,519	333	246 (73.9)	111 (33.3)	135 (40.5)	231 (69.4)
			[68.9–78.3]	[28.5–38.6]	[35.4–45.9]	[64.2–74.1]
Johannesburg B	435,241	197	169 (85.8)	55 (27.9)	114 (57.9)	152 (77.2)
			[80.2–90.0]	[22.1–34.6]	[50.9–64.6]	[70.8–82.5]
Johannesburg C	799,980	444	363 (81.8)	139 (31.3)	224 (50.5)	356 (80.2)
			[77.9–85.1]	[27.2–37.2]	[45.8–43.5]	[76.2–83.6]
Johannesburg D	1,396,243	646	472 (73.1)	216 (33.4)	256 (39.6)	450 (69.7)
			[69.5–76.3]	[29.9–37.2]	[35.9–43.5]	[66.0–73.1]
Johannesburg E	601,433	161	117 (72.7)	60 (37.3)	57 (35.4)	113 (70.2)
			[65.3–79.0]	[30.1–45.0]	[28.4–43.1]	[62.7–76.7]
Johannesburg F	751,484	243	185 (76.1)	80 (32.9)	105 (43.2)	172 (70.8)
			[70.4–81.1]	[27.3–39.1]	[37.1–49.5]	[64.8–76.2]
Johannesburg G	842,339	444	329 (74.1)	133 (30.0)	196 (44.1)	318 (71.6)
			[69.7–77.8]	[25.8–34.3]	[39.5–48.7]	[67.1–75.5]
Ekurhuleni District	3,825,650	1861	1382 (74.3)	597 (32.1)	785 (42.2)	1305 (70.1)
			[72.2–76.2]	[30.0–34.2]	[40.0–44.4]	[68.0–72.2]
Ekurhuleni E1	626 517	353	242 (68.6)	124 (35.1)	118 (33.4)	229 (64.9)
			[63.5–73.2]	[30.3–40.3]	[28.7–38.5]	[59.7–69.7]
Ekurhuleni E2	455 262	252	190 (75.4)	81 (32.1)	109 (43.3)	181 (71.8)
			[69.7–80.3]	[26.7–38.2]	[37.3–49.4]	[66.0–77.0]
Ekurhuleni N1	708 290	358	244 (68.2)	124 (34.6)	120 (33.5)	232 (64.8)
			[63.1–72.8]	[29.9–39.7]	[28.8–38.6]	[59.7–69.6]
Ekurhuleni N2	697 175	258	206 (79.8)	63 (24.4)	143 (55.4)	177 (68.6)
			[74.5–84.3]	[19.6–30.0]	[49.3–61.4]	[62.7–74.0]
Ekurhuleni S1	673 758	210	172 (81.9)	76 (36.2)	96 (45.7)	169 (80.5)
			[76.1-86.5]	[30.0-42.9]	[39.1–52.5]	[74.6-85.3]
Ekurhuleni S2	664 648	430	328 (76.3)	129 (30.0)	199 (46.3)	317 (73.7)
			[72.0–80.1]	[25.9–34.5]	[41.6–51.0]	[69.4–77.7]

			[66.5–74.0]	[29.6–37.3]	[33.2–41.1]	[64.7–72.3]
Lesedi	127 419	408	292 (71.6)	150 (36.8)	142 (34.8)	286 (70.1)
			[67.0–75.7]	[32.2–41.6]	[30.3–39.6]	[65.5–74.3]
Midvaal	126 285	104	65 (62.5)	26 (25.0)	39 (37.5)	63 (60.6)
			[52.8–71.3]	[17.6–34.2]	[28.7–47.2]	[50.9–69.5]
Emfuleni	830 798	52	40 (76.9)	12 (23.1)	28 (53.8)	38 (73.1)
			[63.6-86.4]	[13.6–36.4]	[40.3–66.8]	[59.5–83.4]
City of Tshwane	3,709,635	1464	976 (66.7)	471 (32.2)	505 (34.5)	939 (64.1)
District			[54.2-69.0]	[29.8-34.6]	[32.1–36.9]	[61.6-66.5]
Tshwane 1	1 032 885	471	298 (63.3)	145 (30.8)	153 (32.5)	287 (60.9)
			[58.8–67.5]	[26.8-35.1]	[28.4–36.8]	[56.4–65.2]
Tshwane 2	436 950	175	103 (58.9)	57 (32.6)	46 (26.3)	99 (56.6)
			[51.4-65.9]	[26.0-39.9]	[20.3–33.3]	[49.1–63.7]
Tshwane 3	730 788	229	177 (77.3)	72 (31.4)	105 (45.9)	167 (72.9)
			[71.4–82.3]	[25.8–37.7]	[39.5–52.3]	[66.8–78.3]
Tshwane 4	482 448	78	46 (59.0)	19 (24.4)	27 (34.6)	44 (56.4)
			[47.8–69.3]	[16.1–35.1]	[24.9–45.8]	[45.3–66.9]
Tshwane 5	119 190	204	129 (63.2)	72 (35.3)	57 (27.9)	126 (61.8)
			[56.4–69.6]	[29.0-42.1]	[22.2–34.5]	[54.9–68.2]
Tshwane 6	768 446	245	175 (71.4)	89 (36.3)	86 (35.1)	169 (69.0)
			[65.5–76.7]	[30.5–42.5]	[29.4–41.3]	[62.9–74.5]
Tshwane 7	138 928	62	48 (77.4)	17 (27.4)	31 (50.0)	47 (75.8)
			[64.2-85.1]	[17.5–39.2]	[37.2–61.4]	[62.5–83.8]
West Rand District	950 <i>,</i> 088	653	489 (74.9)	225 (34.5)	264 (40.4)	483 (74.0)
			[71.4–78.1]	[30.9–38.2]	[36.7–44.2]	[70.5–77.2]
Mogale City	435 254	149	95 (63.8)	51 (34.2)	44 (29.5)	95 (63.8)
			[55.7–71.1]	[27.1–42.2]	[22.8–37.3]	[55.7–71.1]
Rand West City	300 960	261	208 (79.7)	92 (35.2)	116 (44.4)	207 (79.3)
			[74.4–84.1]	[29.7–41.2]	[38.5–50.5]	[74.0–83.8]
Merafong City	213 874	243	196 (76.5)	82 (33.7)	104 (42.8)	181 (74.5)
			[70.8-81.4]	[28.1–39.9]	[36.7–49.1]	[68.6–79.6]

CI, confidence interval

Seroprevalence was calculated as the number of individuals seropositive for anti-S or anti-N IgG divided by the total number of individuals sampled. Confidence intervals have not been adjusted for multiplicity and should not be used for inference.

	Wave 1*	Wave 2*	Wave 3*	Wave 4*	TOTAL
Dominant variant	Wild type	Beta	Delta	Omicron	
Period of wave	Mar 7–Nov 13, 2020	Nov 14, 2020–Mar 30, 2021	Mar 31–Oct 25, 2021	Oct 26, 2021–Jan 12, 2022	Mar 7, 2020–Jar 12, 2022
Age group: 0–4 years		,		,	,
Cases in wave – no.†	2761	2005	6709	4724	16,199
Case rate per 100,000 population	212	154	514	362	1241
Proportion of total cumulative cases, %	17.0	12.4	41.4	29.2	100
Age group: 5–19 years					
Cases in wave – no.†	14,798	12,892	53,636	26,067	107,393
Case rate per 100,000 population	435	379	1575	766	3154
Proportion of total cumulative cases, %	13.8	12.0	49.9	24.3	100
Age group: 20–49 years					
Cases in wave – no.†	148,240	112,919	300,032	147,270	708,461
Case rate per 100,000 population	1818	1385	3680	1806	8690
Proportion of total cumulative cases, %	20.9	15.9	42.3	20.8	100
Age group: 50–59 years					
Cases in wave – no.†	35,434	27,584	81,120	25,408	169,546
Case rate per 100,000 population	2695	2098	6169	1932	12,894
Proportion of total cumulative cases, %	20.9	16.3	47.8	15.0	100
Age group: >60 years					
Cases in wave – no.†	30,896	27,164	70,142	23,462	151,664
Case rate per 100,000 population	2358	2073	5353	1791	11,576
Proportion of total cumulative cases, %	20.4	17.9	46.2	15.5	100
Sex: male [‡]					
Cases in wave – no.†	98,223	80,612	229,407	99,837	508,079
Case rate per 100,000 population	1267	1040	2958	1287	6552
Proportion of total cumulative cases, %	19.3	15.9	45.2	19.6	100
Sex: female [‡]					
Cases in wave – no.†	132,425	100,661	278,826	125,338	637,250
Case rate per 100,000 population	1712	1302	3605	1621	8240
Proportion of total cumulative cases, %	20.8	15.8	43.8	19.7	100.0

Table S5. Number and incidence per 100,000 population of Covid-19 cases, in Gauteng Province by Covid-19 wave, stratified by age and by gender.

*All data are from the National Institute for Communicable Diseases daily databases. The Omicron-dominant fourth case wave is at its tail-end but has not yet fully subsided. Totals, incidence, and proportions of cases are anticipated to continue to increase somewhat over the next few weeks until the wave has fully subsided. †Changes in testing rates, particularly the lower rates during Wave 1 due to constraints in laboratory capacity and prioritization of testing for hospitalized individuals, prevent direct comparisons, especially in terms of cases numbers during the first wave in relation to the subsequent waves. Cases include asymptomatic and symptomatic individuals. Cumulative reported cases were sourced from the National Department of Health.¹² *Sex was not recorded for 7895 Covid-19 cases, who are excluded from analyses by sex.

	Wave 1*	Wave 2*	Wave 3*	Wave 4*	TOTAL
Dominant variant	Wild type	Beta	Delta	Omicron	
Period of wave	Mar 7–Nov 13,	Nov 14, 2020–Mar	Mar 31–Oct 25, 2021	Oct 26, 2021–Jan	Mar 7, 2020–Jai
	2020	30, 2021		12, 2022	12, 2022
Age group: 0–4 years					
Hospitalisations in wave – no.†	523	724	1377	1288	3912
Hospitalisation rate per 100,000 population	40	55	106	99	300
Proportion of total cumulative hospitalisations, %	13.4	18.5	35.2	32.9	100
Age group: 5–19 years					
Hospitalisations in wave – no.†	745	683	1551	1118	4097
Hospitalisation rate per 100,000 population	22	20	46	33	120
Proportion of total cumulative hospitalisations, %	18.2	16.7	37.9	27.3	100
Age group: 20–49 years					
Hospitalisations in wave – no. ⁺	13,882	11,914	21,028	7650	54,474
Hospitalisation rate per 100,000 population	170	146	258	94	668
Proportion of total cumulative hospitalisations, %	25.5	21.9	38.6	14.0	100
Age group: 50–59 years					
Hospitalisations in wave – no.†	6755	6828	12,888	1673	28,144
Hospitalisation rate per 100,000 population	514	519	980	127	2140
Proportion of total cumulative hospitalisations, %	24.0	24.3	45.8	5.9	100
Age group: >60 years					
Hospitalisations in wave – no.†	11,712	11,318	23,615	4159	50,804
Hospitalisation rate per 100,000 population	894	864	1802	317	3878
Proportion of total cumulative hospitalisations, %	23.1	22.3	46.5	8.2	100
Sex: male [‡]					
Hospitalisations in wave – no.†	15,237	14,590	29,255	6663	65,745
Hospitalisation rate per 100,000 population	196	188	377	86	848
Proportion of total cumulative hospitalisations, %	23.2	22.2	44.5	10.1	100
Sex: female [‡]					-
Hospitalisations in wave – no.†	18,323	16,850	31,155	9198	75,526
Hospitalisation rate per 100,000 population	237	218	403	119	977
Proportion of total cumulative hospitalisations, %	24.3	22.3	41.3	12.2	100
	v				

Table S6. Number and incidence per 100,000 population of hospitalizations in Gauteng Province by Covid-19 wave, stratified by age and by gender.

*All data are from DATCOV, hosted by the National Institute for Communicable Disease,⁷ as described previously.⁹ The system was developed during the course of the first wave, with gradual onboarding of facilities; hence, these data could underestimate hospitalized cases in the first wave relative to subsequent waves. The hospitalized cases include individuals with Covid-19, as well as coincidental infections identified as part of routine testing for SARS-CoV-2 of individuals admitted to the facilities to assist in triaging of patients in the hospital. The Omicron-dominant fourth case wave is at its tail-end but has not yet fully subsided. Totals, incidence, and proportions of hospitalizations are anticipated to continue to increase somewhat over the next few weeks until the wave has fully subsided. ⁺Changes in testing rates, particularly the lower rates during Wave 1 due to constraints in laboratory capacity and prioritization of testing for hospitalized individuals, prevent direct comparisons, especially in terms of case numbers during the first wave in relation to the subsequent waves. ⁺Sex was not recorded for 162 hospitalizations, who are excluded from analyses by sex.

	Wave 1*	Wave 2*	Wave 3*	Wave 4*	TOTAL
Dominant variant	Wild type	Beta	Delta	Omicron	
Period of wave	Mar 7–Nov 13,	Nov 14, 2020–	Mar 31–Oct 25, 2021	Oct 26, 2021–Jan	Mar 7, 2020–Jai
	2020	Mar 30, 2021		6, 2022	6, 2022
Age group: 0–4 years					
Recorded deaths in wave – no.	36	22	49	19	126
Recorded death rate per 100,000 population	3	2	4	1	10
Proportion of total cumulative recorded deaths, %	28.6	17.5	38.9	15.1	100
Age group: 5–19 years					
Recorded deaths in wave – no.	24	15	51	22	112
Recorded death rate per 100,000 population	1	0	1	1	3
Proportion of total cumulative recorded deaths, %	21.4	13.4	45.5	19.6	100
Age group: 20–49 years					
Recorded deaths in wave – no.	1184	1309	2566	299	5358
Recorded death rate per 100,000 population	15	16	31	4	66
Proportion of total cumulative recorded deaths, %	22.1	24.4	47.9	5.6	100
Age group: 50–59 years					
Recorded deaths in wave – no.	1195	1465	3144	146	5950
Recorded death rate per 100,000 population	91	111	239	11	452
Proportion of total cumulative recorded deaths, %	20.1	24.6	52.8	2.5	100
Age group: >60 years					
Recorded deaths in wave – no.	3730	4058	8873	692	17,353
Recorded death rate per 100,000 population	285	310	677	53	1324
Proportion of total cumulative recorded deaths, %	21.5	23.4	51.1	4.0	100
Sex: male [‡]					
Recorded deaths in wave – no.	3245	3317	7806	601	14,969
Recorded death rate per 100,000 population	42	43	101	8	193
Proportion of total cumulative recorded deaths, %	21.7	22.2	52.1	4.0	100
Sex: female [†]				-	
Recorded deaths in wave – no.	2919	3551	6864	573	13,907
Recorded death rate per 100,000 population	38	46	89	7	180
Proportion of total cumulative recorded deaths, %	21.0	25.5	49.4	4.1	100

Table S7. Number and incidence per 100,000 population of recorded deaths in Gauteng Province by Covid-19 wave, stratified by age and by gender.

*All data are from the National Department of Health.¹² The Omicron-dominant fourth case wave is at its tail-end but has not yet fully subsided. Totals, incidence, and proportions of deaths are anticipated to continue to increase somewhat over the next few weeks until the waves has fully subsided. [†]Sex was not recorded for 22 recorded deaths, who are excluded from analyses by sex.

Supplementary References

1. Mutevedzi PC, Kawonga M, Kwatra G, et al. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. Int J Epidemiol 2021:doi: 10.1093/ije/dyab217.

2. Africa Centers for Disease Control and Prevention. Generic protocol for a population-based, age- and gender-stratified sero-survey study for SARS-CoV-2.

https://africacdc.org/download/generic-protocol-for-a-population-based-age-and-gender-stratifiedsero-survey-study-for-sars-cov-2/: Africa Centers for Disease Control and Prevention; 2020.

3. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020.

https://apps.who.int/iris/handle/10665/331656: World Health Organization; 2020.

4. Kwatra G, Nunes M, Dhar N, et al. Correlation of dried blood spots and plasma for quantification of Immunoglobulin (IgG) against Receptor binding domain and full length spike protein of SARS-CoV-2. J Virol Methods 2021;300:114394.

5. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 2020;57:e100.

6. Simani OE, Izu A, Violari A, et al. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. AIDS 2014;28:531-41.

7. South African National Institute for Communicable Diseases. Daily Hospital Surveillance (DATCOV) Report. <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/</u>: South African National Institute for Communicable Diseases; 2022.

8. South African National Institute for Communicable Diseases. Weekly Hospital Surveillance (DATCOV) Update. <u>https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-hospital-surveillance-datcov-update/</u>: South African National Institute for Communicable Diseases; 2022.

9. Jassat W, Mudara C, Ozougwu L, et al. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet Glob Health 2021;9:e1216-e25.

10. World Health Organization. COVID-19: Surveillance, case investigation and epidemiological protocols - Case-based reporting form. <u>https://www.who.int/publications/i/item/case-based-reporting-form</u>: World Health Organization; 2021.

11. South African Medical Research Council. Report on Weekly Deaths in South Africa. <u>https://www.samrc.ac.za/sites/default/files/files/2022-01-12/weekly8Jan2022.pdf</u>: South African Medical Research Council; 2022.

12. South African Department of Health. COVID-19 Online Resource & News Portal. https://sacoronavirus.co.za/: South African Department of Health; 2021-2022.

13. South African National Institute for Communicable Diseases. COVID-19 Weekly Epidemiology Brief: Week 1 2022. <u>https://www.nicd.ac.za/wp-content/uploads/2022/01/COVID-19-Weekly-</u> <u>Epidemiology-Brief-week-1-2022.pdf</u>: South African National Institute for Communicable Diseases; 2022.

14. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org2022:<u>https://ourworldindata.org/coronavirus</u>.

15. Statistics South Africa. STATISTICAL RELEASE P0302: Mid-year population estimates 2020. http://www.statssa.gov.za/publications/P0302/P03022020.pdf: Statistics South Africa; 2021.